N-(6-Fluorobenzothiazol-2-yl)-5-(p-tolyl)furan-2-carboxamide

ID: ALA4475561

PubChem CID: 155537985

Max Phase: Preclinical

Molecular Formula: C19H13FN2O2S

Molecular Weight: 352.39

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Cc1ccc(-c2ccc(C(=O)Nc3nc4ccc(F)cc4s3)o2)cc1

Standard InChI:  InChI=1S/C19H13FN2O2S/c1-11-2-4-12(5-3-11)15-8-9-16(24-15)18(23)22-19-21-14-7-6-13(20)10-17(14)25-19/h2-10H,1H3,(H,21,22,23)

Standard InChI Key:  CUCNBWASSZITNW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   14.5058   -2.2080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5046   -3.0276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2127   -3.4365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2109   -1.7992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9195   -2.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9243   -3.0230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7043   -3.2715    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   17.1817   -2.6064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.6966   -1.9470    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.9989   -2.6015    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.4116   -3.3068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2288   -3.3020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.0072   -4.0169    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.7966   -3.4356    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   19.7095   -3.9627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4852   -3.7056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4804   -2.8884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7017   -2.6406    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.1403   -2.4053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.8893   -2.7349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.5471   -2.2513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4572   -1.4382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7038   -1.1110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0491   -1.5966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1148   -0.9531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 11 13  2  0
  2 14  1  0
 12 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 12  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 17 19  1  0
 22 25  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4475561

    ---

Associated Targets(Human)

LRRK2 Tchem Leucine-rich repeat serine/threonine-protein kinase 2 (6390 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 352.39Molecular Weight (Monoisotopic): 352.0682AlogP: 5.26#Rotatable Bonds: 3
Polar Surface Area: 55.13Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.98CX Basic pKa: CX LogP: 5.17CX LogD: 5.17
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.55Np Likeness Score: -2.42

References

1. Zaldivar-Diez J, Li L, Garcia AM, Zhao WN, Medina-Menendez C, Haggarty SJ, Gil C, Morales AV, Martinez A..  (2020)  Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate.,  63  (5): [PMID:31825616] [10.1021/acs.jmedchem.9b01752]

Source